Addition of Talazoparib to Maintenance Atezolizumab Improves Survival Outcomes for Patients With SLFN11-Positive Extensive-Stage Small Cell Lung Cancer
According to phase 2 study results, the addition of talazoparib, a PARP inhibitor, to maintenance atezolizumab improved survival outcomes among patients with Schlafen 11 (SLFN11)-positive extensive-stage small cell lung cancer (SCLC).
In this study, 106 patients were randomized to receive front-line chemotherapy plus atezolizumab followed by either atezolizumab alone (n = 52) or in combination with talazoparib (n = 54). The primary end point was progression-free survival (PFS). Key secondary end points included overall survival (OS), and safety.
At analysis, the median PFS was 2.4 months in the atezolizumab alone arm and 2.9 months in the talazoparib arm (hazard ratio [HR], 0.66; 80% confidence interval [CI], 0.50 to 0.86; P = .019). There was no difference in OS between the 2 treatment arms (HR, 0.98; 80% CI, 0.71 to 1.36; P = .47). Grade ≥3 non-hematologic treatment-related adverse events occurred in 14% of patients in the atezolizumab alone arm and 17% of patients in the talazoparib arm. Grade ≥3 hematological treatment-related adverse events occurred in 4% and 50% of patients, respectively (P < .001).
As study authors concluded, “prospective biomarker-selection was demonstrated, paving the way for future evaluation of novel therapies in molecularly defined SCLC populations.”
Source:
Karim NA, Miao J, Reckamp KL, et al. Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. J Thorac Oncol. Published online: November 3, 2024. doi: 10.1016/j.jtho.2024.10.021
